KORU Medical Systems, Inc. (KRMD)
NASDAQ: KRMD · Real-Time Price · USD
4.080
+0.020 (0.49%)
Apr 28, 2026, 4:00 PM EDT - Market closed
KORU Medical Systems Revenue
In the year 2025, KORU Medical Systems had annual revenue of $41.13M with 22.23% growth. KORU Medical Systems had revenue of $10.90M in the quarter ending December 31, 2025, with 23.27% growth.
Revenue (ttm)
$41.13M
Revenue Growth
+22.23%
P/S Ratio
4.61
Revenue / Employee
$563,389
Employees
73
Market Cap
189.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.13M | 7.48M | 22.23% |
| Dec 31, 2024 | 33.65M | 5.13M | 17.98% |
| Dec 31, 2023 | 28.52M | 621.63K | 2.23% |
| Dec 31, 2022 | 27.90M | 4.41M | 18.76% |
| Dec 31, 2021 | 23.49M | -686.27K | -2.84% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Feb 28, 2017 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Embecta | 1.08B |
| AngioDynamics | 313.73M |
| OraSure Technologies | 115.02M |
| Sanara MedTech | 103.12M |
| Pro-Dex | 72.10M |
| Utah Medical Products | 37.53M |
| Stereotaxis | 32.38M |
| Nyxoah | 11.76M |
KRMD News
- 12 days ago - KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026 - Business Wire
- 6 weeks ago - KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility - Business Wire
- 6 weeks ago - KORU Medical Systems Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - KORU Medical Systems Announces CEO Transition - Business Wire
- 6 weeks ago - KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance - Business Wire
- 2 months ago - KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Business Wire
- 3 months ago - KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System - Business Wire
- 3 months ago - KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow - Business Wire